Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their ...

Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk factors, ...

Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.

Choosing between Recursion Pharmaceuticals (NASDAQ:RXRX) and Summit Therapeutics (NASDAQ:SMMT) requires weighing the broad potential of artificial intelligence against the specific clinical prospects ...

Earnings Call Insights Recursion Pharmaceuticals outlines focused R&D pipeline with multiple catalysts through 2026 SA InsightsMon, May 05, 2025 2 Comments ...

Abstract: In this paper, some new schemes are developed to improve the tracking performance for fast and rapidly time-varying systems. A generalized recursive least-squares (RLS) algorithm called the ...

Bearish sentiment remains elevated across several U.S. small-cap stocks, with restaurant operator Jack in the Box topping the ...

Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from ...